Taken together, last decades' radiopharmaceuticals have been primarily targeting tumor cell membrane proteins (B7-H3, CXCR4, FRα, HER2, integrin αVβ3, L1CAM, mesothelin, MISRII and NaPi2b) besides the (intra-)nuclear target PARP-1 and the FAP-associated tumor microenvironment. Here, PARP1 is linked to neoplasm.